Aequus Pharmaceuticals (TSE:AQS) has released an update.
Aequus Pharmaceuticals reports a 77.50% increase in revenue for Q3 2024 compared to the previous year, driven by the continued growth of their product Zimed® PF. The company has restructured to reduce costs amidst delayed profitability, while also exploring strategic alternatives to enhance future performance.
For further insights into TSE:AQS stock, check out TipRanks’ Stock Analysis page.
